Generate Biomedicines, Inc.

DUBLIN--( BUSINESS WIRE )--The "Digital Transformation and Emerging Technologies in the Healthcare Industry 2024 Edition" report has been added to ResearchAndMarkets.com's offering. The report examines the progress of digital transformation in the pharmaceutical industry. It assesses the industry's preparedness to embrace innovation, explores the challenges and opportunities associated with digital transformation as well as highlights current and emerging trends in technology-related investments. The pharmaceutical industry is facing ongoing shifts driven by declining profit margins, increasing cost pressures, and the need to both replenish pipelines and maximize peak sales, all while adhering to strict regulatory and legislative requirements. Although adopting innovative technologies is seen as a key strategy to mitigate these challenges, the digitalization process is complex, time-consuming, and requires significant investment, along with sustained commitment and transparent dialogue with various stakeholders, including employees, investors, and regulators. The pharmaceutical industry is experiencing steady advancement in digital transformation. Mirroring 2023 survey findings, operations enablement and innovation was selected as the main scope of digital transformation in 2024. Optimism regarding the growth of digital transformation in their organizations reached record highs among the pharma industry professionals. In line with previous years' results, lack of specific skills and talents was selected as the top hinderance for digital transformation. Digital privacy and data security issues have ranked as the top concern associated with digital transformation, closely followed by cybersecurity concerns. Strong leadership was regarded as the key driver for a successful digital transformation. Pharma industry professionals are prioritizing artificial intelligence (AI) for current and future investments. Digital transformation is a must for maintaining competitive advantage in the pharmaceutical industry. Scope Benchmark the level of business readiness and technology adoption. Gain a deeper understanding of the business functions affected the most by digital transformation. Identify and assess barriers to adopting emerging technologies. Define the critical requirements for success. Determine the importance of emerging technologies to the pharmaceutical industry. Evaluate current levels of investment and identity both present and future investment priorities. Analyze the impact of COVID-19, inflation, and other factors on digitalization efforts. Explore the impact of emerging technologies on the pharmaceutical value chain. Assess the role of digital transformation in sustaining competitive advantage. Reasons to Buy Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have in the near future. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector. Develop business strategies by understanding the key factors of digital transformation and emerging technology in the healthcare sector. Identify emerging industry trends in the uptake of emerging technologies to gain a competitive advantage. Key Topics Covered: Study Design Key Findings Overview of Digital Transformation Digital Transformation Strategies Digital Transformation Objectives Obstacles to Digital Transformation Concerns Associated with Digital Transformation Necessities for Digital Transformation Emerging Technologies - Investment Trends Artificial Intelligence Case Studies Summary of Key Findings Appendix Competitive Landscape Amgen AB BenevolentAI Ltd Biolexis Therapeutics Inc Cellix Biosciences Inc Eli Lilly and Co Generate Biomedicines Inc Google Cloud Platform Hackensack Meridian Health Inc Healx Ltd Highmark Health InSilico Medicine Mount Sinai Health System Novartis AG Recursion Pharmaceuticals Inc For more information about this report visit https://www.researchandmarkets.com/r/r3umsv About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Protein-making AI models have fueled the launch of a $1 billion startup and a Nobel Prize win in 2024, but are they ready to actually make drugs? Leaders of some of the largest startups working on that question say the technology is promising but not yet ready. But a tiny startup called Nabla Bio is far more bullish, posting a preprint Thursday highlighting its progress in creating antibodies from scratch that look therapeutically viable against some hard-to-drug targets in what it’s calling a first for the field. This isn’t the holy grail of having fully optimized drug candidates at the push of a button. But Nabla’s research is a step forward. The biotech’s leaders say their antibodies showed strong binding affinities and, in general, looked and behaved more like drug candidates than previous de novo efforts. Nabla said these are the first computer-generated antibodies against the family of proteins called GPCRs, which are notoriously hard to drug. The research includes eight examples of de novo antibodies against a range of targets, including proteins found in the membrane of cells like Claudin-4 and CXCR7. “The antibodies are developable, and they could potentially be real drugs,” said Frances Anastassacos, co-founder and president of Nabla. “They will have to go through lead optimization, but unlocking target space is a very exciting space to be. That’s the real promise of de novo design.” Other startups appear to be close behind, if not in lockstep, with Nabla, and that makes its first-ever claims hard to judge. For instance, a California startup called Abalone Bio told Endpoints News it has also generated de novo antibodies targeting GPCRs, the same hard-to-hit protein family cited in Nabla’s preprint. Abalone has not published those results, but presented some of its findings at an antibody engineering conference earlier this month and also framed them as a first for the field. “To our knowledge, these are the first designed GPCR antibody sequences that are functionally active,” its research poster stated. Protein design has arguably become the hottest space when applying AI to biology in 2024. David Baker, a pioneer in the field, won a share of the Nobel Prize in Chemistry last month. He also co-founded Xaira Therapeutics, which launched earlier this year with $1 billion to bring AI into drug R&D, specifically designing antibodies. A year ago, Flagship Pioneering’s Generate:Biomedicines published its own de novo model , called Chroma, and has raised nearly $750 million to build an extensive pipeline of antibody drugs. The leaders of those startups have also acknowledged the limitations of their recent work. Xaira CEO Marc Tessier-Lavigne recently told Endpoints News the AI models can generate initial hit candidates, but those still need to be improved by “old-school methods.” Generate R&D head Alexandra Snyder said earlier this year that designing from scratch isn’t yet ready for prime time, echoing what Baker has acknowledged in his own lab’s research. Despite having a fraction of the resources of Xaira or Generate, Nabla hopes to lead the field. It recently closed a $26 million Series A round and employs 16 people in its 4,500-square-foot lab in Cambridge, MA. CEO Surge Biswas, who co-founded Nabla in 2020 based on his PhD work in Harvard University geneticist George Church’s lab, said technology, rather than capital, is the key limit to progress. “Developing a system like we developed, the scarce commodity is not that you have $100 million to solve this problem,” Biswas said in an interview. “It’s not cheap, but you don’t need to raise giant amounts of capital to unlock some of these technologies.” In an interview, Church called Nabla’s preprint one of “relatively few actual success stories” in applying de novo work for so-called undruggable targets. “My hat is off to them for choosing targets well and not settling for a bunch of academic papers that settle five-decade-old challenges,” Church said. Nabla’s preprint details an AI system called JAM, or Joint Atomic Modeling, in which scientists provide the sequence and structure of a desired drug target. The system then generates antibodies that may fit that target. The most promising creations showed strong binding affinities and looked developable in lab testing, according to the preprint. There are still limitations to Nabla’s findings. They mainly made nanobodies rather than full-sized monoclonal antibodies that are commonplace in the drug industry. The paper included one example of a de novo monoclonal antibody, but that larger size also contributed to a lower binding success rate of 0.0017% for that project. Nabla doesn’t plan to advance these antibodies itself, as the company is focused on partnering with pharma, with ongoing deals with AstraZeneca, Bristol Myers Squibb and Takeda.

Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori Bio and Valo Health, the life sciences incubator and investor told Endpoints News . Vaccine upstart Apriori Bio promoted its president Craig Williams to CEO, and computational-driven Valo Health named former Foundation Medicine CEO Brian Alexander as its new leader, Flagship told Endpoints on Wednesday. Endpoints reported in September that Valo’s interim CEO Graeme Bell had departed. Alexander joins Valo at a pivotal moment. The Boston-area startup expects a Phase 2 readout in diabetic retinopathy by year’s end, a spokesperson told Endpoints in September. Valo is testing OPL-0401, an oral small molecule that inhibits Rho kinase, or ROCK, 1 and 2. The biotech withdrew a different mid-stage drug last year. Alexander started at Valo on Wednesday after joining from Roche, where he was head of the Boston Roche Innovation Center and before that was CEO of Foundation Medicine, the Swiss pharma’s genomic profiling unit. Valo also promoted Brett Blackman, its business and innovation chief, to chief operating officer. At the same time, joining the board is Travis Wilson, a former Stealth BioTherapeutics CEO and now Flagship growth partner. The company launched in 2019 and was set for a $2.8 billion valuation had it followed through with a proposed combination with a special purpose acquisition company. That path to the public markets was nixed in November 2021 . The company later bought another startup, the cardiovascular drug discovery shop TARA Biosystems, and then inked a $60 million upfront and nearly $2.7 billion biobucks deal with Novo Nordisk in the cardiovascular space. Meanwhile, Williams started leading Apriori earlier this month as Flagship general partner Lovisa Afzelius focuses on other biotechs and projects at the incubator. Afzelius has been involved in multiple Flagship-founded startups, including Alltrna, Metaphore, and Generate:Biomedicines. Williams joined Flagship and Apriori last year after helping launch more than 15 vaccines and treatments during his prior roles at GSK. He also spent about three years leading the international unit of ViiV Healthcare, the HIV company owned by GSK, Pfizer and Shionogi, until the fall of 2021. Apriori unveiled $50 million in July 2022 to predict virus variants before new outbreaks occur and create vaccines for viral threats . Williams and Alexander are taking on the CEO-partner roles shortly after Flagship unveiled its $3.6 billion capital haul in July. The firm has also boosted its presence in Singapore , unveiled a few new startups and inked multiple pharma collaborations this year.